ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Also written as “Symbicort Turbuhaler”, “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)” and “Budesonide/formoterol (Symbicort® Turbuhaler®)”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageBudesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 17, 200710 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only80 open or runningphase 4since Dec 17, 2007Oct 6, 2006none ahead
Chenpon Pharmaceutical10 open or runningphase 1since Aug 31, 2026Aug 31, 2026none ahead
Orion Corporation, Orion Pharmaits history only10 open or runningphase 1since Mar 24, 2009Mar 24, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chenpon Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2026First study: phase 1 study in AsthmaFirst studyNCT07804303 · 30 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Chenpon Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07804303Asthma · China1CompletedJan 22, 202430

How it is read

Names in the registry

  • “Symbicort Turbuhaler”, 3 entries
  • “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)”, 1 entry
  • “Budesonide/formoterol (Symbicort® Turbuhaler®)”, 1 entry
  • “Symbicort Turbuhaler (Budesonide/formoterol)”, 1 entry
  • “Budesonide/formoterol (Symbicort Turbuhaler)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.